| NCT ID | NCT07253987 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Masaryk Memorial Cancer Institute |
| Condition | Prostate Cancer Patients |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2025-05-05 |
| Primary Completion | 2026-09-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 200 participants in total. It began in 2025-05-05 with a primary completion date of 2026-09-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The questionnaire for assessment of adverse events after completion of cancer treatment, which is being piloted at the Masaryk Memorial Cancer Institute, aims to detect a wide range of adverse effects early on, thus facilitating adequate intervention and planning of follow-up care for all cancer survivors.
Eligibility Criteria
Inclusion Criteria: * The patient understands the information provided and agrees to participate in the study. * Age 18 years or older. * Histologically confirmed invasive breast cancer or invasive prostate cancer. * Completion of the acute phase of curative oncological therapy: * for breast cancer: curative surgery performed + completed neoadjuvant/adjuvant chemotherapy and completed adjuvant radiotherapy, if indicated * for prostate cancer: completed radiotherapy with curative intent or radical prostatectomy performed (open, laparoscopic, robotic) or completed adjuvant radiotherapy after prostatectomy * The patient is available for follow-up within 12 months of enrollment in the study. Exclusion Criteria: * Active ongoing oncological therapy (except for (i) adjuvant hormone therapy, (ii) adjuvant targeted therapy (anti-HER2 therapy, CDK4/6i, PARPi, T-DM1), (iii) adjuvant immunotherapy) * Neoadjuvant/adjuvant therapy did not include chemotherapy (breast cancer). * Recurrence of cancer * Metastatic disease * History of other primary malignancy (except for non-melanoma skin cancer)
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07253987 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Prostate Cancer Patients. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07253987 currently recruiting?
Yes, NCT07253987 is actively recruiting participants. Contact the research team at lenka.pavcikova@mou.cz for enrollment information.
Where is the NCT07253987 trial being conducted?
This trial is being conducted at Brno, Czechia.
Who is sponsoring the NCT07253987 clinical trial?
NCT07253987 is sponsored by Masaryk Memorial Cancer Institute. The trial plans to enroll 200 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.